IBT is addressing urgent medical needs in the premature infant

5-10% of the smallest premature infants develop necrotizing enterocolitis (NEC), a potentially lethal disorder in which portions of the bowel undergo tissue death. A key goal in the treatment of preterm infants is achievement of full enteral feeding as early as possible to optimize growth (and to improve longer term clinical outcomes.
Read More

IBT is developing medicines to be approved by FDA, EMA and other medicines agencies

To ensure adequate production quality and to assess the risks and benefits of medicines that treat a disease, drugs must be approved by a regulatory medicines agency before use. This review is particularly important given the vulnerability of the preterm babies. To date no dietary/probiotic product on the market has been approved by these regulatory agencies. IBT is committed to develop the first live bacterial product by following the agency requirements.
Read More

What is the Connection Study?

The Connection study is the first ever regulatory medicines agency approved phase 3 study on the potential benefits of any live bacterial therapy in premature infants.
Read More

Join the effort - Join the Connection Study

Read More